Financials
CHRISTUS Stehlin Foundation for Cancer Research was organized in 1969 as a Texas non-profit corporation. It received original designation from the Internal Revenue Service as a tax-exempt organization under Internal Revenue Code Section 501 (c)(3) in May 1969. Its Employer Identification Number (EIN) is 74-1622404.
Audited Financial Statements
The Foundation has retained independent certified public accountants since inception to review its annual financial results, and independent accountants reconcile the Foundation’s financial records each month. Copies of recent statements and the related auditors’ report may be reviewed or downloaded below. The Foundation’s fiscal year ends on June 30.
If you wish to examine earlier statements, please contact the Foundation office.
Tax Returns
Though exempt from federal taxation, the Foundation is required to file an information return annually with the Internal Revenue Service. The Foundation’s Forms 990 for recent years are available for viewing and download by clicking the links below. Earlier returns are available for inspection at the Foundation office or by using the Foundation Center’s 990 Finder (just enter EIN 741622404).
Form 990 for tax year:
IRS Determination of Exempt Status
The Foundation’s principal purpose and function is to perform medical research. The Internal Revenue Service specifies that donors may deduct contributions to the Foundation from their Federal income taxes as provided in section 170 of the Internal Revenue Code. All bequests, legacies, devises, transfers, or gifts to the Foundation are deductible for Federal estate and gift tax purposes if they meet the applicable provisions of sections 2055, 2106, and 2522 of the Code.
Featured Events
19th Annual Susan’s Rally
April 22, 2012
Combining a spirit of fun with a worthy philanthropic effort, Susan's Rally takes participants on an afternoon adventure in their automobiles and raises money for the fight against breast cancer!
About the Foundation
“There’s a lot of excitement about the new drugs and projects on the horizon, but it takes a lot of money to make those possibilities come true. That’s why we’re here – to raise money. We just always have a good time doing it.”
Mike Meagher,
Founder, Friends of Stehlin Foundation
News
In Mice, Cancer Drug Shows Effect on Alzheimer's Symptoms
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
Genetic Breakthrough for Brain Cancer in Children
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.
Stay Connected
Affiliates and Resources
